Wise Road Capital

Frank Zhengyi Tang, the Founding Partner, serves as the central decision-maker and public-facing lead for all major acquisitions and fund strategy. The firm maintains a deliberately lean investment team, and no formal investment committee structure beyond Tang's office has been publicly detailed. This concentrated authority allows rapid execution on cross-border semiconductor deals.

Wise Road Capital sources primarily through government-facilitated introductions to distressed or divestiture-bound semiconductor assets in the US, Europe, and South Korea. The firm targets companies facing regulatory pressure, cyclical downturns, or parent-company carve-outs where the seller's need for a clean exit aligns with Wise Road's ability to bypass typical auction processes through pre-negotiated bilateral deals.

The firm executes control buyouts in the semiconductor and advanced manufacturing sectors, typically targeting companies with $100 million to $500 million in revenue. Post-acquisition, Wise Road Capital relocates manufacturing capabilities, intellectual property, and distribution networks into China's domestic market. The strategy is structured around China's semiconductor import substitution goals rather than traditional financial engineering or multiple arbitrage.

Wise Road Capital conducts direct control investments almost exclusively. While the firm raises capital through limited partner commitments for specific acquisition funds — notably the $7.5 billion chip fund launched in 2021 — it does not operate as a fund-of-funds or commit third-party capital into external managers. The firm's LPs include Chinese state-owned platforms and regional government guidance funds.

Wise Road Capital has encountered repeated CFIUS rejections in the United States and European Union foreign direct investment screening blocks on semiconductor acquisitions. These regulatory outcomes have functionally redirected the firm toward European wafer fabrication and South Korean display-related chip assets where seller-side distress outweighs national security objections. Some acquisitions have later been unwound by host governments, most notably when the UK ordered the divestiture of Nexperia's Newport Wafer Fab in 2022.

While structured as a private equity firm, Wise Road Capital's limited partner base is dominated by Chinese state-owned investment platforms and regional government guidance funds. The firm's investment mandate directly mirrors the semiconductor self-sufficiency targets outlined in China's Made in China 2025 policy, giving it a quasi-sovereign function even though it raises capital through standard fund structures.

Wise Road Capital structures acquisitions through club-deal formats involving Chinese state capital and occasionally other China-aligned private equity firms. The firm has not historically invited Western institutional co-investors, given the regulatory friction many of its deals generate in the United States and European Union. Co-investment terms are not publicly disclosed.